AE_label_raw
AE leading to discontinuation
Abdominal distension
Abdominal pain
Abdominal pain upper
Acute cholecystitis
Acute gallbladder diseases
Acute kidney injury
Acute pancreatitis
Acute renal events
Acute renal failure
Adverse event leading to permanent trial-product discontinuation
Adverse event leading to withdrawal
Adverse events
Adverse events in ≥5% of patients
Adverse events leading to discontinuation of drug or placebo
Adverse events leading to discontinuation of retatrutide or placebo
Adverse events leading to discontinuation of trial drug or placebo
Adverse events leading to discontinuation of trial product
Adverse events leading to discontinuation of trial regimen
Adverse events leading to trial product discontinuation
Alanine aminotransferase of at least 3 times the ULN
Alanine aminotransferase of at least 5 times the ULN
Allergic reactions
Alopecia
Antidrug antibodies during treatment
Any AE
Any GI adverse event
Any ISR
Any TEAE
Any adverse event
Any adverse event during treatment
Any adverse events
Any hypoglycaemic event
Any serious AE
Any serious TEAE
Appendicitis
Arthralgia
Atrial fibrillation or flutter
Back pain
Benign and malignant neoplasms
Biliary disorder
Bilirubin of at least twice the ULN
Bladder prolapse
Breast cancer
Bronchitis
COVID-19
CV events
Cancer
Cardiac arrhythmia
Cardiac disorders
Cardiovascular disorders
Cellulitis
Chest pain
Cholecystitis
Cholecystitis acute
Cholelithiasis
Chronic cholecystitis
Constipation
Covid-19
Death
Deaths
Decreased appetite
Depressive disorder or suicidal behavior or ideation
Diabetic retinopathy
Diarrhea
Diarrhoea
Discontinuation as a result of a TEAE
Discontinued drug due to a drug-related adverse event
Discontinued drug due to an adverse event
Dizziness
Documented hypoglycemia (<54 mg/dL)
Documented symptomatic hypoglycaemic event
Drug-related adverse events
Drug-related hepatic disorders
Dyspepsia
Early satiety
Eructation
Fatal event
Fatal events
Fatigue
Feeling jittery
Flatulence
GERD
Gallbladder disease
Gallbladder-related disorders
Gallbladder-related events
Gastro-oesophageal reflux disease
Gastroenteritis
Gastroesophageal reflux disease
Gastrointestinal adverse event leading to discontinuation
Gastrointestinal adverse events
Gastrointestinal adverse events: Abdominal pain
Gastrointestinal adverse events: Constipation
Gastrointestinal adverse events: Nausea
Gastrointestinal disorders
Gastrointestinal disorders (any)
Gastrointestinal leading adverse events to permanent trial-product discontinuation
Haematological neoplasia
Headache
Heart-rate increase
Hepatic disorder
Hepatic disorders
Hepatic events
Hepatobiliary disorders
Hyperesthesia or related adverse event
Hypersensitivity
Hypersensitivity syndrome or symptoms
Hypertension
Hypoglycaemia
Hypoglycaemic episodes
Hypoglycemia
Hypoglycemia (blood glucose <54 mg/dl)
Increase in lipase level
Influenza
Injection site bruising
Injection site reactions
Injection-site hematoma
Injection-site reaction
Injection-site reactions
Intervertebral disc protrusion
Major (adjudication-confirmed) adverse cardiovascular events
Major adverse cardiovascular event
Major depressive disorder or suicidal ideation
Malaise
Malignant neoplasm
Malignant neoplasms
Mild ISR event
Nasopharyngitis
Nausea
Neck pain
Neoplasms
No. of patients with one or two ISR events among patients with an ISR
Osteoarthritis
Pain
Pain in extremity
Pancreatic cancer
Pancreatitis
Pancreatitis (adjudication-confirmed)
Pancreatitis acute
Participants with ≥1 adverse event during treatment period
Pneumonia
Psychiatric disorders
Related adverse event
Renal disorders
Renal event
Renal events
Renal impairment
Retching
Serious adverse event
Serious adverse events
Serious adverse events in ≥0.2% of patients
Serious drug-related adverse events
Serious gastrointestinal events
Severe gastrointestinal adverse event
Severe hypoglycaemia
Severe hypoglycaemic event
Severe hypoglycemia
Severe or serious GI events
Severe or serious gastrointestinal events
Sinusitis
Symptomatic hypoglycemia
Thyroid cancer
Total adverse events
Total serious adverse events
Upper abdominal pain
Upper respiratory tract infection
Upper-respiratory-tract infection
Urinary tract infection
Urinary-tract infection
Uterine leiomyoma
Vomiting
Withdrawal due to an ISR
